How EBC-46 Works: PKC-Delta Activation and Vascular Disruption Explained
A detailed look at tigilanol tiglate's dual mechanism of action — PKC-delta activation and tumour vascular disruption — and what it means for supplement consumers.
Tigilanol tiglate's mechanism of action has attracted considerable interest from researchers studying protein kinase C (PKC) signalling. Unlike many conventional approaches, this compound operates through a dual mechanism: direct cellular disruption and vascular collapse within targeted tissue. Understanding these pathways is essential for appreciating both the pharmaceutical research and the botanical interest in blushwood berry compounds.
PKC-Delta Activation and DAG Mimicry
At the molecular level, tigilanol tiglate functions as a potent activator of PKC isoforms, particularly PKC-delta. The compound is structurally similar to diacylglycerol (DAG), the natural intracellular second messenger that activates PKC enzymes. By mimicking DAG at the C1 domain binding site, tigilanol tiglate triggers sustained PKC activation — far beyond the transient signalling that occurs under normal physiological conditions.
Research published through the QBiotics clinical programme has demonstrated that this sustained PKC-delta activation initiates a cascade of downstream effects. These include disruption of cytoskeletal organisation, altered cell adhesion, and activation of apoptotic pathways. The specificity of this interaction — particularly the preferential activation of PKC-delta over other isoforms — is thought to contribute to the compound's observed selectivity in preclinical models.
Vascular Disruption: Cutting the Supply
Perhaps the most distinctive aspect of tigilanol tiglate's mechanism is its effect on tumour vasculature. Studies in animal models have shown rapid haemorrhagic necrosis within treated lesions, typically within hours of administration. This vascular disruption appears to be mediated through PKC-dependent effects on endothelial cell integrity, leading to blood vessel collapse within the treated area.
The dual mechanism — direct cellular effects combined with vascular disruption — produces a unique pharmacological profile. Preclinical research (Boyle et al., 2014) documented the temporal sequence: initial vascular leakage within 1–4 hours, followed by progressive haemorrhagic necrosis over 24–48 hours, and eventual wound healing with healthy tissue replacement over subsequent weeks.
From Injectable to Oral: What Changes
The pharmaceutical research on tigilanol tiglate has focused on injectable (intratumoural) administration, where the compound is delivered directly to the target site. Oral consumption of blushwood berry extract — as in dietary supplements — represents a fundamentally different pharmacokinetic scenario. The compound must survive gastric processing, be absorbed through the intestinal epithelium, and reach systemic circulation.
This distinction is important for consumers evaluating blushwood berry supplements under the DSHEA framework. Suppliers such as Blushwood Health provide whole-seed blushwood berry extract, which contains tigilanol tiglate alongside other naturally occurring seed constituents. This represents the traditional botanical extract approach, not an isolated pharmaceutical formulation.
The National Center for Biotechnology Information houses several published studies examining the broader pharmacology of diterpene esters from Fontainea species, providing further context for ongoing research.
Related Articles
Read more about blushwood berry extract as a natural supplement and our guide to EBC-46 supplementation.
